{"id":22657,"date":"2025-01-23T14:47:11","date_gmt":"2025-01-23T06:47:11","guid":{"rendered":"https:\/\/flcube.com\/?p=22657"},"modified":"2025-01-23T14:47:32","modified_gmt":"2025-01-23T06:47:32","slug":"imbioray-raises-rmb-100-million-in-series-a-for-nk-cell-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22657","title":{"rendered":"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies"},"content":{"rendered":"\n

Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK\/CAR raNK and tiNK cell products.<\/p>\n\n\n\n

Platform and Pipeline Development<\/strong>
Founded in 2014, iMBIORAY has established a robust platform for developing innovative cell therapies. The company’s platforms include the CAR-raNK-ADC platform for introducing CARs into NK cells, the tiNK immune domestication NK cell platform, the ANKERTM antibody-guided NK connector platform, and mRNA vaccine technology. These platforms position iMBIORAY at the forefront of developing next-generation NK cell therapies. <\/p>\n\n\n\n

Future Outlook<\/strong>
With the Series A+ financing, iMBIORAY is poised to accelerate its clinical programs and bring its universal NK cell therapies closer to market. The funding will support the development of its lead candidates and the commercialization of its off-the-shelf NK cell products, addressing significant unmet needs in oncology and immunotherapy.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7…<\/p>\n","protected":false},"author":1,"featured_media":22659,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,20,3259],"class_list":["post-22657","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-finance","tag-imbioray"],"yoast_head":"\niMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK\/CAR raNK and tiNK cell products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22657\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies\" \/>\n<meta property=\"og:description\" content=\"Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK\/CAR raNK and tiNK cell products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22657\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-23T06:47:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-23T06:47:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2310-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"530\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies\",\"datePublished\":\"2025-01-23T06:47:11+00:00\",\"dateModified\":\"2025-01-23T06:47:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657\"},\"wordCount\":211,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2310-png.avif\",\"keywords\":[\"Cell-therapy\",\"Finance\",\"iMBIORAY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22657#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22657\",\"name\":\"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2310-png.avif\",\"datePublished\":\"2025-01-23T06:47:11+00:00\",\"dateModified\":\"2025-01-23T06:47:32+00:00\",\"description\":\"Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK\\\/CAR raNK and tiNK cell products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22657\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2310-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/2310-png.avif\",\"width\":1080,\"height\":530,\"caption\":\"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22657#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies - Insight, China's Pharmaceutical Industry","description":"Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK\/CAR raNK and tiNK cell products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22657","og_locale":"en_US","og_type":"article","og_title":"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies","og_description":"Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK\/CAR raNK and tiNK cell products.","og_url":"https:\/\/flcube.com\/?p=22657","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-23T06:47:11+00:00","article_modified_time":"2025-01-23T06:47:32+00:00","og_image":[{"width":1080,"height":530,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2310-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22657#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22657"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies","datePublished":"2025-01-23T06:47:11+00:00","dateModified":"2025-01-23T06:47:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22657"},"wordCount":211,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=22657#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2310-png.avif","keywords":["Cell-therapy","Finance","iMBIORAY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22657#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22657","url":"https:\/\/flcube.com\/?p=22657","name":"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=22657#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=22657#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2310-png.avif","datePublished":"2025-01-23T06:47:11+00:00","dateModified":"2025-01-23T06:47:32+00:00","description":"Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series A+ financing round. The round was led by Sinowisdom, with contributions from Tailong VC, HY Capital, and other investors. The proceeds will be used to advance the clinical development of universal natural killer (NK) cell therapies, including IBR854, IBR733, IBR822, and IBR900, as well as the market launch of peripheral blood-derived, non-viral vector, non-gene edited off-the-shelf universal immune domestication NK\/CAR raNK and tiNK cell products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22657#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22657"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=22657#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2310-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2310-png.avif","width":1080,"height":530,"caption":"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22657#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/2310-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22657"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22657\/revisions"}],"predecessor-version":[{"id":22661,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22657\/revisions\/22661"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/22659"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}